Form 4: Hims & Hers CEO Andrew Dudum Executes Stock Option and Sells Shares Under 10b5-1 Plan

Hims & Hers CEO Andrew Dudum exercised stock options and sold a portion of his holdings in Class A Common Stock on January 16, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Dudum, CEO of Hims & Hers Health, Inc., executed a stock option to acquire 33,668 shares of Class A Common Stock at $2.43 per share on January 16, 2025.
• On the same day, Mr. Dudum sold a total of 77,960 shares of Class A Common Stock at prices ranging from $26.70 to $28.105 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following these transactions, Mr. Dudum directly owns 27,918 shares and indirectly owns a total of 9,703,113 shares through various trusts.
• The indirect holdings include shares held by the Dudum Family Community Property Trust, Andrew Dudum 2015 Trust, and several GRATs (Grantor Retained Annuity Trusts).

Sentiment

Score: 5

Explanation: The document is a routine filing of insider trading activity, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests a planned transaction, not a reaction to new information.

Risks

• The sale of a significant number of shares by the CEO could be perceived negatively by the market, potentially impacting the stock price.
• The reliance on a 10b5-1 trading plan suggests a predetermined strategy for selling shares, which may not always align with the company's best interests.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice for executives to manage their stock holdings while avoiding accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the healthcare and technology sectors, such as Teladoc Health and GoodRx.
• The reported sale prices are within the typical range for stock transactions by executives, and the volume of shares sold is not unusual for a CEO's holdings.
• The use of GRATs and other trusts for managing personal wealth is also a common practice among high-net-worth individuals, including corporate executives.

Stakeholder Impact

• The sale of shares by the CEO could potentially cause short-term fluctuations in the stock price, impacting shareholders.
• The transactions do not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, insider trading, stock options, 10b5-1 plan, Andrew Dudum, Hims & Hers Health, share sales, executive compensation, Class A Common Stock